0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
ICU-acquired Acute Kidney Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: November 2024
|
Report Code: QYRE-Auto-15U6016
Home | Market Reports | Health| Health Conditions
Global ICU acquired Acute Kidney Treatment Market Insights and Forecast to 2028
BUY CHAPTERS

ICU-acquired Acute Kidney Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-15U6016
Report
November 2024
Pages:90
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

ICU-acquired Acute Kidney Treatment - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

ICU-acquired Acute Kidney Treatment - Market

ICU-acquired Acute Kidney Treatment - Market

The global market for ICU-acquired Acute Kidney Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for ICU-acquired Acute Kidney Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of ICU-acquired Acute Kidney Treatment by region & country, by Type, and by Application.
The ICU-acquired Acute Kidney Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ICU-acquired Acute Kidney Treatment.
Market Segmentation

Scope of ICU-acquired Acute Kidney Treatment - Market Report

Report Metric Details
Report Name ICU-acquired Acute Kidney Treatment - Market
CAGR 5%
Segment by Type:
  • Pre-renal
  • Intrinsic-renal
  • Post-renal
Segment by Application
  • Public Hospital
  • Private Hospital
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Quark Pharmaceuticals, Fresenius Medical Care, B. Braun, Baxter international, Angion Biomedica Corp, Asahi Kasei Medical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of ICU-acquired Acute Kidney Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of ICU-acquired Acute Kidney Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of ICU-acquired Acute Kidney Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the ICU-acquired Acute Kidney Treatment - Market report?

Ans: The main players in the ICU-acquired Acute Kidney Treatment - Market are Quark Pharmaceuticals, Fresenius Medical Care, B. Braun, Baxter international, Angion Biomedica Corp, Asahi Kasei Medical

What are the Application segmentation covered in the ICU-acquired Acute Kidney Treatment - Market report?

Ans: The Applications covered in the ICU-acquired Acute Kidney Treatment - Market report are Public Hospital, Private Hospital

What are the Type segmentation covered in the ICU-acquired Acute Kidney Treatment - Market report?

Ans: The Types covered in the ICU-acquired Acute Kidney Treatment - Market report are Pre-renal, Intrinsic-renal, Post-renal

Recommended Reports

Kidney Disease Markets

Urinary Tract Disorders

ICU & Acute Care

1 Market Overview
1.1 ICU-acquired Acute Kidney Treatment Product Introduction
1.2 Global ICU-acquired Acute Kidney Treatment Market Size Forecast
1.3 ICU-acquired Acute Kidney Treatment Market Trends & Drivers
1.3.1 ICU-acquired Acute Kidney Treatment Industry Trends
1.3.2 ICU-acquired Acute Kidney Treatment Market Drivers & Opportunity
1.3.3 ICU-acquired Acute Kidney Treatment Market Challenges
1.3.4 ICU-acquired Acute Kidney Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global ICU-acquired Acute Kidney Treatment Players Revenue Ranking (2023)
2.2 Global ICU-acquired Acute Kidney Treatment Revenue by Company (2019-2024)
2.3 Key Companies ICU-acquired Acute Kidney Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies ICU-acquired Acute Kidney Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of ICU-acquired Acute Kidney Treatment
2.6 ICU-acquired Acute Kidney Treatment Market Competitive Analysis
2.6.1 ICU-acquired Acute Kidney Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by ICU-acquired Acute Kidney Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ICU-acquired Acute Kidney Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Pre-renal
3.1.2 Intrinsic-renal
3.1.3 Post-renal
3.2 Global ICU-acquired Acute Kidney Treatment Sales Value by Type
3.2.1 Global ICU-acquired Acute Kidney Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global ICU-acquired Acute Kidney Treatment Sales Value, by Type (2019-2030)
3.2.3 Global ICU-acquired Acute Kidney Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Public Hospital
4.1.2 Private Hospital
4.2 Global ICU-acquired Acute Kidney Treatment Sales Value by Application
4.2.1 Global ICU-acquired Acute Kidney Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global ICU-acquired Acute Kidney Treatment Sales Value, by Application (2019-2030)
4.2.3 Global ICU-acquired Acute Kidney Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global ICU-acquired Acute Kidney Treatment Sales Value by Region
5.1.1 Global ICU-acquired Acute Kidney Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global ICU-acquired Acute Kidney Treatment Sales Value by Region (2019-2024)
5.1.3 Global ICU-acquired Acute Kidney Treatment Sales Value by Region (2025-2030)
5.1.4 Global ICU-acquired Acute Kidney Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America ICU-acquired Acute Kidney Treatment Sales Value, 2019-2030
5.2.2 North America ICU-acquired Acute Kidney Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe ICU-acquired Acute Kidney Treatment Sales Value, 2019-2030
5.3.2 Europe ICU-acquired Acute Kidney Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific ICU-acquired Acute Kidney Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific ICU-acquired Acute Kidney Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America ICU-acquired Acute Kidney Treatment Sales Value, 2019-2030
5.5.2 South America ICU-acquired Acute Kidney Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa ICU-acquired Acute Kidney Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa ICU-acquired Acute Kidney Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions ICU-acquired Acute Kidney Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions ICU-acquired Acute Kidney Treatment Sales Value
6.3 United States
6.3.1 United States ICU-acquired Acute Kidney Treatment Sales Value, 2019-2030
6.3.2 United States ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States ICU-acquired Acute Kidney Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe ICU-acquired Acute Kidney Treatment Sales Value, 2019-2030
6.4.2 Europe ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe ICU-acquired Acute Kidney Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China ICU-acquired Acute Kidney Treatment Sales Value, 2019-2030
6.5.2 China ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China ICU-acquired Acute Kidney Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan ICU-acquired Acute Kidney Treatment Sales Value, 2019-2030
6.6.2 Japan ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan ICU-acquired Acute Kidney Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea ICU-acquired Acute Kidney Treatment Sales Value, 2019-2030
6.7.2 South Korea ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea ICU-acquired Acute Kidney Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia ICU-acquired Acute Kidney Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia ICU-acquired Acute Kidney Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India ICU-acquired Acute Kidney Treatment Sales Value, 2019-2030
6.9.2 India ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India ICU-acquired Acute Kidney Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Quark Pharmaceuticals
7.1.1 Quark Pharmaceuticals Profile
7.1.2 Quark Pharmaceuticals Main Business
7.1.3 Quark Pharmaceuticals ICU-acquired Acute Kidney Treatment Products, Services and Solutions
7.1.4 Quark Pharmaceuticals ICU-acquired Acute Kidney Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Quark Pharmaceuticals Recent Developments
7.2 Fresenius Medical Care
7.2.1 Fresenius Medical Care Profile
7.2.2 Fresenius Medical Care Main Business
7.2.3 Fresenius Medical Care ICU-acquired Acute Kidney Treatment Products, Services and Solutions
7.2.4 Fresenius Medical Care ICU-acquired Acute Kidney Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Fresenius Medical Care Recent Developments
7.3 B. Braun
7.3.1 B. Braun Profile
7.3.2 B. Braun Main Business
7.3.3 B. Braun ICU-acquired Acute Kidney Treatment Products, Services and Solutions
7.3.4 B. Braun ICU-acquired Acute Kidney Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Baxter international Recent Developments
7.4 Baxter international
7.4.1 Baxter international Profile
7.4.2 Baxter international Main Business
7.4.3 Baxter international ICU-acquired Acute Kidney Treatment Products, Services and Solutions
7.4.4 Baxter international ICU-acquired Acute Kidney Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Baxter international Recent Developments
7.5 Angion Biomedica Corp
7.5.1 Angion Biomedica Corp Profile
7.5.2 Angion Biomedica Corp Main Business
7.5.3 Angion Biomedica Corp ICU-acquired Acute Kidney Treatment Products, Services and Solutions
7.5.4 Angion Biomedica Corp ICU-acquired Acute Kidney Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Angion Biomedica Corp Recent Developments
7.6 Asahi Kasei Medical
7.6.1 Asahi Kasei Medical Profile
7.6.2 Asahi Kasei Medical Main Business
7.6.3 Asahi Kasei Medical ICU-acquired Acute Kidney Treatment Products, Services and Solutions
7.6.4 Asahi Kasei Medical ICU-acquired Acute Kidney Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Asahi Kasei Medical Recent Developments
8 Industry Chain Analysis
8.1 ICU-acquired Acute Kidney Treatment Industrial Chain
8.2 ICU-acquired Acute Kidney Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 ICU-acquired Acute Kidney Treatment Sales Model
8.5.2 Sales Channel
8.5.3 ICU-acquired Acute Kidney Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
    Table 1. ICU-acquired Acute Kidney Treatment Market Trends
    Table 2. ICU-acquired Acute Kidney Treatment Market Drivers & Opportunity
    Table 3. ICU-acquired Acute Kidney Treatment Market Challenges
    Table 4. ICU-acquired Acute Kidney Treatment Market Restraints
    Table 5. Global ICU-acquired Acute Kidney Treatment Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global ICU-acquired Acute Kidney Treatment Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies ICU-acquired Acute Kidney Treatment Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies ICU-acquired Acute Kidney Treatment Product Type
    Table 9. Key Companies Time to Begin Mass Production of ICU-acquired Acute Kidney Treatment
    Table 10. Global ICU-acquired Acute Kidney Treatment Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ICU-acquired Acute Kidney Treatment as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global ICU-acquired Acute Kidney Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global ICU-acquired Acute Kidney Treatment Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global ICU-acquired Acute Kidney Treatment Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global ICU-acquired Acute Kidney Treatment Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global ICU-acquired Acute Kidney Treatment Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global ICU-acquired Acute Kidney Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global ICU-acquired Acute Kidney Treatment Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global ICU-acquired Acute Kidney Treatment Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global ICU-acquired Acute Kidney Treatment Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global ICU-acquired Acute Kidney Treatment Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global ICU-acquired Acute Kidney Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global ICU-acquired Acute Kidney Treatment Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global ICU-acquired Acute Kidney Treatment Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global ICU-acquired Acute Kidney Treatment Sales Value by Region (2019-2024) & (%)
    Table 27. Global ICU-acquired Acute Kidney Treatment Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions ICU-acquired Acute Kidney Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions ICU-acquired Acute Kidney Treatment Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions ICU-acquired Acute Kidney Treatment Sales Value, (2025-2030) & (US$ Million)
    Table 31. Quark Pharmaceuticals Basic Information List
    Table 32. Quark Pharmaceuticals Description and Business Overview
    Table 33. Quark Pharmaceuticals ICU-acquired Acute Kidney Treatment Products, Services and Solutions
    Table 34. Revenue (US$ Million) in ICU-acquired Acute Kidney Treatment Business of Quark Pharmaceuticals (2019-2024)
    Table 35. Quark Pharmaceuticals Recent Developments
    Table 36. Fresenius Medical Care Basic Information List
    Table 37. Fresenius Medical Care Description and Business Overview
    Table 38. Fresenius Medical Care ICU-acquired Acute Kidney Treatment Products, Services and Solutions
    Table 39. Revenue (US$ Million) in ICU-acquired Acute Kidney Treatment Business of Fresenius Medical Care (2019-2024)
    Table 40. Fresenius Medical Care Recent Developments
    Table 41. B. Braun Basic Information List
    Table 42. B. Braun Description and Business Overview
    Table 43. B. Braun ICU-acquired Acute Kidney Treatment Products, Services and Solutions
    Table 44. Revenue (US$ Million) in ICU-acquired Acute Kidney Treatment Business of B. Braun (2019-2024)
    Table 45. B. Braun Recent Developments
    Table 46. Baxter international Basic Information List
    Table 47. Baxter international Description and Business Overview
    Table 48. Baxter international ICU-acquired Acute Kidney Treatment Products, Services and Solutions
    Table 49. Revenue (US$ Million) in ICU-acquired Acute Kidney Treatment Business of Baxter international (2019-2024)
    Table 50. Baxter international Recent Developments
    Table 51. Angion Biomedica Corp Basic Information List
    Table 52. Angion Biomedica Corp Description and Business Overview
    Table 53. Angion Biomedica Corp ICU-acquired Acute Kidney Treatment Products, Services and Solutions
    Table 54. Revenue (US$ Million) in ICU-acquired Acute Kidney Treatment Business of Angion Biomedica Corp (2019-2024)
    Table 55. Angion Biomedica Corp Recent Developments
    Table 56. Asahi Kasei Medical Basic Information List
    Table 57. Asahi Kasei Medical Description and Business Overview
    Table 58. Asahi Kasei Medical ICU-acquired Acute Kidney Treatment Products, Services and Solutions
    Table 59. Revenue (US$ Million) in ICU-acquired Acute Kidney Treatment Business of Asahi Kasei Medical (2019-2024)
    Table 60. Asahi Kasei Medical Recent Developments
    Table 61. Key Raw Materials Lists
    Table 62. Raw Materials Key Suppliers Lists
    Table 63. ICU-acquired Acute Kidney Treatment Downstream Customers
    Table 64. ICU-acquired Acute Kidney Treatment Distributors List
    Table 65. Research Programs/Design for This Report
    Table 66. Key Data Information from Secondary Sources
    Table 67. Key Data Information from Primary Sources
    Table 68. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. ICU-acquired Acute Kidney Treatment Product Picture
    Figure 2. Global ICU-acquired Acute Kidney Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global ICU-acquired Acute Kidney Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 4. ICU-acquired Acute Kidney Treatment Report Years Considered
    Figure 5. Global ICU-acquired Acute Kidney Treatment Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by ICU-acquired Acute Kidney Treatment Revenue in 2023
    Figure 7. ICU-acquired Acute Kidney Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Pre-renal Picture
    Figure 9. Intrinsic-renal Picture
    Figure 10. Post-renal Picture
    Figure 11. Global ICU-acquired Acute Kidney Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 12. Global ICU-acquired Acute Kidney Treatment Sales Value Market Share by Type, 2023 & 2030
    Figure 13. Product Picture of Public Hospital
    Figure 14. Product Picture of Private Hospital
    Figure 15. Global ICU-acquired Acute Kidney Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global ICU-acquired Acute Kidney Treatment Sales Value Market Share by Application, 2023 & 2030
    Figure 17. North America ICU-acquired Acute Kidney Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 18. North America ICU-acquired Acute Kidney Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 19. Europe ICU-acquired Acute Kidney Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 20. Europe ICU-acquired Acute Kidney Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 21. Asia Pacific ICU-acquired Acute Kidney Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 22. Asia Pacific ICU-acquired Acute Kidney Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 23. South America ICU-acquired Acute Kidney Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 24. South America ICU-acquired Acute Kidney Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 25. Middle East & Africa ICU-acquired Acute Kidney Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 26. Middle East & Africa ICU-acquired Acute Kidney Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 27. Key Countries/Regions ICU-acquired Acute Kidney Treatment Sales Value (%), (2019-2030)
    Figure 28. United States ICU-acquired Acute Kidney Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 29. United States ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 30. United States ICU-acquired Acute Kidney Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 31. Europe ICU-acquired Acute Kidney Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 32. Europe ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 33. Europe ICU-acquired Acute Kidney Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 34. China ICU-acquired Acute Kidney Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 35. China ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 36. China ICU-acquired Acute Kidney Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 37. Japan ICU-acquired Acute Kidney Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 38. Japan ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 39. Japan ICU-acquired Acute Kidney Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 40. South Korea ICU-acquired Acute Kidney Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 41. South Korea ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 42. South Korea ICU-acquired Acute Kidney Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 43. Southeast Asia ICU-acquired Acute Kidney Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 45. Southeast Asia ICU-acquired Acute Kidney Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 46. India ICU-acquired Acute Kidney Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 47. India ICU-acquired Acute Kidney Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 48. India ICU-acquired Acute Kidney Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 49. ICU-acquired Acute Kidney Treatment Industrial Chain
    Figure 50. ICU-acquired Acute Kidney Treatment Manufacturing Cost Structure
    Figure 51. Channels of Distribution (Direct Sales, and Distribution)
    Figure 52. Bottom-up and Top-down Approaches for This Report
    Figure 53. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS